Portfolio Lab

Astrazeneca PLC

  • Stock
  • Ticker AZN
  • ISIN GB0009895292
  • NYSE
  • US listing in dollars

Health care · Pharmaceuticals · United Kingdom

$174.35 −0.60%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Astrazeneca PLC since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

AZNGlobal equities (VT)

$10,000 grew to $42,533. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −27.9% in 11/2024, measured from the peak in 08/2024. It took 13 months to get back to the old peak.

1-year return
+1.0%
5-year return p.a.
+11.5%
10-year return p.a.
+15.6%
Volatility p.a.
22.1%
Largest decline
−27.9%

Financial statements

Amounts in $ millions from the company's annual financial reports, earnings per share in $ per ordinary share

Fiscal year202020212022202320242025
Income statement
Revenue26,61737,41744,35145,81154,07358,739
Gross profit21,31824,98031,96037,54343,86648,106
Operating income5,1621,0563,7578,19310,00313,743
EBITDA8,3117,5869,237–––
Net income3,1441153,2935,9617,04110,233
Earnings per share2.440.082.113.814.506.54
Balance sheet
Total assets66,729105,36396,483101,119104,035114,074
Liabilities51,09166,07659,42561,95363,16465,355
Equity15,63839,28737,05839,16640,87148,719
Cash7,8326,3296,1665,8405,4885,711
Long-term debt17,50528,13422,96522,36526,50624,715
Cash flow
Operating cash flow4,7995,9639,80810,34511,86114,575
Capital expenditure-961-1,091-1,091-1,361-1,924-2,810
Free cash flow3,8384,8728,7178,9849,93711,765

Annual returns

Best year 2025 at +43.3%, weakest 2024 at −0.6%. 8 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€245bn
Market cap in trading currency
$270bn
Enterprise value
$292bn
P/E
26.7
P/S
4.60
P/B
5.55
EV/Sales
4.97
EV/EBITDA
–
Earnings yield
3.8%
FCF yield
4.4%

Results (latest fiscal year)

Revenue
$58.7bn
Gross profit
$48.1bn
EBITDA
–
Net income
$10.2bn
Earnings per share
$6.54
Revenue growth
+8.6%
Earnings growth
+45.3%

Profitability

Gross margin
81.9%
Operating margin
23.4%
Net margin
17.4%
Return on equity
22.9%
Return on assets
9.0%

Balance sheet and cash flow

Cash
$5.71bn
Financial debt
$27.8bn
Debt/equity %
57
Current ratio
0.94
Book value per share
$31.41
Operating cash flow
$14.6bn
Free cash flow
$11.8bn

Dividend

Dividend yield
3.08%
Dividend (12 months)
$5.37
Yield (12 months)
3.08%
Payout ratio
49%
Ex-dividend date
7 Aug 2026

Shares and trading

Shares outstanding
1.55bn
Volume
2.00m
Avg. volume 3 months
2.93m
Relative volume
0.7

Price and technicals

Price
$174.35
1 day
−0.6%
52-week high
$209.48
52-week low
$155.62
Distance to 52-week high
−16.8%
Distance to 52-week low
+12.0%
Distance to 50-day line
+2.1%
Distance to 200-day line
−3.1%
RSI (14)
44
Volatility 1M
32.0%

Performance

1 week
−5.5%
1 month
+1.0%
3 months
+4.6%
6 months
−6.8%
YTD
−5.2%
1 year
−2.0%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has AZN performed since 11/2016?

$10,000 grew to $42,533 by 20 Nov 2026, which is +15.6% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is AZN?

Volatility was 22.1% per year, measured on monthly returns. The largest decline from a peak was −27.9%, with the low in 11/2024.

How does AZN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, AZN returned +15.6% at 22.1%. The correlation of monthly returns was 0.30; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's listing traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Astrazeneca PLC (AZN): Return and risk | Portfolio Lab